B44.0
Conditions
Interventions
Group 1: The study population consists of patients from the anesthesiology intensive care units
who were treated with isavocunazole including therapeutic drug monitoring.
Sponsors
Klinik für Anaesthesiologie, LMU Klinikum, Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The study population consists of patients from anesthesiology intensive care units who were treated with isavocunazole including therapeutic drug monitoring. The patients consist of the typical subgroups of these wards, i.e. some of the patients some of the patients had received donor organ transplants (liver, lung, heart) and approximately half of the patients had undergone renal replacement surgery due to renal failure.
Exclusion criteria
Exclusion criteria: Diagnosis-specific exclusion of specific patients does not take place.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Influencing factors on isavuconazole concentration in critically ill patients | — |
Secondary
| Measure | Time frame |
|---|---|
| - To analyze whether the therapeutically effective drug levels can be achieved with regular application in intensive care patients can be achieved - to evaluate whether, and if so in how many cases, remission of invasive aspergillosis could be achieved with isavocunazole - to develop a pharmacometric model that predicts concentration-time courses for future patients | — |
Countries
Germany
Contacts
Public ContactDanilo Hackner
Klinik für Anaesthesiologie, LMU Klinikum, Campus Großhadern
Outcome results
None listed